Budesonide

synthetic glucocorticoid, locally acting

Also sold as Entocort EC, Uceris.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Scope is oral and GI budesonide only (Crohn's disease of the ileum and ascending colon, and mild to moderate ulcerative colitis). The project brief places the drug at ClinCalc Top 300 (2024) rank 193, a line that also aggregates inhaled and nasal use; that figure was not independently opened and does not describe the oral products. Budesonide has no classical depletion machinery in the label text reviewed: it is a CYP3A4 substrate with 9% to 21% oral bioavailability and 80% to 90% first-pass metabolism, no unchanged drug appears in urine, and the extracted label sections report no CYP induction or inhibition by budesonide itself, no chelation, and no transporter or tubular effect [1][2][3]. No entry in this dossier reaches red or orange. Six entries are yellow and three are ungraded.

synthetic glucocorticoid, locally acting · ATC A07EA06 (corticosteroids acting locally) [5] · also sold as Entocort EC and Uceris and generics · reviewed 2026-10-04. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Budesonide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Bone mineral density (outcome entry, not a calcium or vitamin D deficiency)

Yellow — Low

See study details

In steroid-naive Crohn's patients, 2-year BMD loss on budesonide was small (-1.04%) and about a quarter of that on prednisolone (-3.84%); there is no untreated comparator and the disease itself lowers BMD.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

Null and negative findings: Vitamin D and PTH did not differ between budesonide-exposed and unexposed IBD patients [10]. No fractures in 4 years mean follow-up in that cohort [10]. Cochrane authors state that long-term adrenal and bone effects remain unknown [9].
At-risk subgroups: Pediatric patients (17% higher exposure, growth velocity reduction per label), moderate hepatic impairment (3.5-fold AUC), strong CYP3A4 inhibitor co-exposure (eight-fold AUC with ketoconazole), and patients switched from or combined with systemic corticosteroids [1].

Regulatory status

Label states BMD "decreased significantly less with ENTOCORT EC than with prednisolone in steroid-naive patients" and directs monitoring of patients with osteoporosis; no vitamin D or calcium requirement is stated [1][3]. Tier A.

Population evidence

Schoon et al., double-blind randomized trial, 34 centers, 2 years, n=272 (98 steroid-naive, 83 steroid-exposed, 90 steroid-dependent), budesonide controlled-release versus prednisolone. Steroid-naive: mean BMD change -1.04% versus -3.84% (P=0.0084); no significant difference in the other two strata [6]. A retrospective matched cohort (52 IBD patients on budesonide for 24 months or more, mean 46.1 months, 88% Crohn's disease, versus 52 matched unexposed) found femoral BMD stable in the budesonide group, lumbar spine BMD improved (P=0.002), no fractures in either group, and no major difference in final vitamin D or PTH [10]. A microscopic colitis meta-analysis (4 studies, 276 patients) found OR 2.13 for low bone density versus controls, with numerically about twice as many non-budesonide patients developing osteoporosis as budesonide maintenance patients [11]. A narrative review reports no increase in fracture risk versus untreated controls with long-term low-dose maintenance [7].

Mechanism

Not demonstrated for budesonide in the sources opened. Systemic glucocorticoid exposure is the proposed pathway; budesonide systemic availability is 9% to 21% with 80% to 90% first-pass loss [1]. Systemic effects are dose and formulation dependent (hypercorticism signs in 34% of 427 patients in 8-week trials, label) [1].

Class extrapolation

The prednisolone arm in [6] is a systemic corticosteroid comparator in the same trial; it shows the class effect on BMD and is not extrapolated to budesonide. Budesonide-specific results take priority. No separate systemic-corticosteroid bone study was opened in this review.

Counter-evidence held on record

Confounding by indication is presumed: Crohn's disease and microscopic colitis carry independent low-BMD risk [11], and the active-comparator design of [6] cannot show that budesonide itself causes any loss. The retrospective cohort [10] relied on records and had more vitamin D supplementation in the budesonide group (27% versus 19%). Low BMD is an outcome, not a calcium or vitamin D deficiency, and this entry does not claim either nutrient is depleted. No supplementation is recommended here; bone-protective decisions belong to the prescriber.

Potassium (low serum potassium as a loss disturbance, with strong confounders)

Yellow — Low

See study details

Hypokalemia is listed among laboratory abnormalities at 1% or more in oral budesonide trials and appears in case reports, but no placebo-adjusted rate was found and diarrhea, resection and diuretics are competing explanations.

Full detail and limits

Limits on what this shows

Null and negative findings: The Uceris label does not list hypokalemia among common adverse reactions [4]. The Cochrane induction review (14 studies, 1805 participants) reports no significant increase in adverse events versus placebo and did not highlight potassium [8].
At-risk subgroups: Patients with high-output diarrhea, short-bowel or resection history [13], and patients on potassium-wasting concomitant drugs [12]; pediatric and hepatic impairment (higher exposure) [1].

Regulatory status

Entocort EC label lists hypokalemia, leukocytosis, anemia and others as laboratory abnormalities at 1% or more incidence; the Uceris label lists no hypokalemia among its most common reactions (decreased blood cortisol 4.3%, headache 11.4%) [3][4]. Tier A, listing only.

Population evidence

Label laboratory listing from controlled trials (no per-arm rate extracted) [3]. Case report: a 40-year-old woman with Crohn's disease, prior ileal (50 cm) and colonic (15 cm) resection, severe hypokalemia with rhabdomyolysis, authors cite budesonide as a possible contributor, resolved with potassium normalization [13]. Tier B (case report). A narrative review calls hypokalemia a common adverse effect without a rate [12].

Mechanism

Not established in the sources opened. A mineralocorticoid-type renal potassium loss was not demonstrated for budesonide in the material reviewed.

Class extrapolation

None applied. Systemic-corticosteroid potassium effects are not extrapolated to budesonide in this entry, given its far lower systemic exposure.

Counter-evidence held on record

Diarrhea and bowel resection in Crohn's disease are sufficient competing explanations for low serum potassium. The label listing does not state whether the rate exceeded placebo. This is a serum loss or redistribution disturbance, not a dietary shortfall, and it does not imply that potassium intake should rise. No potassium supplement is recommended; any correction is a prescriber decision after a measured level.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden (class extrapolation, budesonide not in the studied cohort)

Yellow — Low

Evidence: class extrapolation

Glucocorticoid models show dose- and duration-dependent mitochondrial effects; budesonide was not studied in them, its systemic exposure is far lower, and the one budesonide cell study found upregulated oxidative phosphorylation genes.

Full detail and limits

Limits on what this shows

Null and negative findings: No study found measured mitochondrial function in budesonide-treated patients, so there is no null result either.
At-risk subgroups: Not defined. Higher-exposure groups (pediatric, hepatic impairment, CYP3A4 inhibitors) are the only plausible concern [1].

Regulatory status

No mitochondrial statement in the label sections extracted [1][3].

Population evidence

No human budesonide study. Tier C: a review of mitochondrial glucocorticoid receptor work, drugs studied dexamethasone, corticosterone and cortisol, "no data on budesonide"; short exposure raised biogenesis and membrane potential, long exposure impaired the respiratory chain [20]. Tier C: corticosterone in primary rat cortical neurons, inverted-U effect on mitochondrial calcium holding capacity, oxidation and membrane potential, budesonide not studied [21]. Tier B (budesonide in vitro): pancreatic cancer cell lines, budesonide 5 to 20 micromolar in 2D culture and down to about 0.01 micromolar in 3D; GR-dependent upregulation of oxidative phosphorylation genes [19].

Mechanism

Mitochondrial glucocorticoid receptor signaling is the proposed pathway [20][21]. Applicability to budesonide is theoretical because its systemic bioavailability is 9% to 21% [1] and the cancer-cell result [19] is a different system and concentration regime.

Class extrapolation

Labeled class extrapolation. Cohort test: drugs actually studied were dexamethasone, corticosterone and cortisol [20][21]; budesonide was absent. Real class-member data exist, mechanism is plausible but untested for budesonide, so yellow at most. Shares evidence with ATP production and Oxidative stress (see Overlap map).

Counter-evidence held on record

The budesonide-specific study [19] shows an increase, not impairment, in oxidative phosphorylation genes. The class reviews describe biphasic effects driven by dose and duration that are not comparable to low systemic budesonide exposure. Do not present this as mitochondrial damage by budesonide. It is a hypothesis carried from other glucocorticoids and no supplement is indicated.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress (class extrapolation, mixed direction)

Yellow — Low

Evidence: class extrapolation

Class-level data point both ways (long glucocorticoid exposure raising ROS; one IBD cohort showing lower free thiols with corticosteroids), while the only budesonide cell study found budesonide itself had no antioxidant effect.

Full detail and limits

Limits on what this shows

Null and negative findings: No difference in total antioxidant status or uric acid by corticosteroid use [22]; no antioxidant effect of budesonide alone in vitro [18].
At-risk subgroups: Not defined.

Regulatory status

No oxidative-stress statement in the label sections extracted [1][3].

Population evidence

Tier C: review [20] reports increased ROS generation with long glucocorticoid exposure (drugs studied listed above, no budesonide). Tier C, cohort test weak: cross-sectional study of 175 participants (57 controls, 71 ulcerative colitis, 47 Crohn's disease) found lower serum free thiols in corticosteroid-treated IBD patients (43 on corticosteroids), no difference in uric acid or total antioxidant status; the specific corticosteroids were not named and budesonide was not mentioned [22]. Tier B (budesonide in vitro): A549 and activated THP-1 cells, budesonide 1 to 100 micromolar, budesonide alone showed no significant antioxidant effect against H2O2 plus LPS; protection came from the cyclodextrin carrier [18].

Mechanism

Mitochondrial ROS under prolonged glucocorticoid exposure [20]; unproven for budesonide.

Class extrapolation

Labeled class extrapolation. Cohort test: [20] studied dexamethasone, corticosterone, cortisol; [22] did not identify which corticosteroids were used, so budesonide presence cannot be confirmed and that source supports only a hedged yellow. Shares evidence with Mitochondrial burden and ATP production (Overlap map). Free-thiol decline in [22] is confounded by disease activity.

Counter-evidence held on record

Active IBD itself is a pro-oxidant state, and corticosteroid use in [22] tracks with more severe disease. An editor may reasonably downgrade this entry to ungraded because the corticosteroid cohort is unspecified. This is not an antioxidant-depletion claim. No antioxidant supplement is supported by this entry.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No budesonide-specific or usable class-level copper or ceruloplasmin evidence was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition: no Tier B or C evidence located to support a yellow, and no circulating claim about budesonide and copper located to rebut as white. Classification is tooling-limited, not a confirmed literature gap. This is not a finding of safety.

What was found

One budesonide-plus-copper/ceruloplasmin/zinc web query returned only generic copper deficiency, Wilson disease and IBD trace-element pages with no budesonide data; none was cited. Label sections extracted mention no copper effect [1][3].

Channels tried

WebSearch: one budesonide-specific phrasing returned zero relevant results (clean zero for that phrasing); class-level corticosteroid/ceruloplasmin query not executed because the search budget (200 of 200) was exhausted. PubMed search and eutils: HTTP 403 on CONNECT from shell, HTTP 429 via fetch proxy; PubMed abstract pages returned metadata only. Crossref: 429. Europe PMC REST: 429. Semantic Scholar: 429. OpenAlex search: 429 (single-record lookup worked once but had no target record). DailyMed and FDA label: opened. Unpaywall: no response from shell, not retried by another route.

Iron

Not graded — disclosed evidence gap

See study details

No budesonide-attributable change in iron status was found; the label's anemia listing cannot be read as an iron finding.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition: no Tier B or C evidence located and no circulating iron claim for budesonide located. Tooling-limited and provisional; not a finding of safety and not independent of the disease-driven iron deficiency of IBD.

What was found

The Entocort EC label lists anemia among laboratory abnormalities at 1% or more [3]; no iron, ferritin or transferrin saturation data for budesonide-treated patients were found, and anemia is not iron deficiency (Hard Rule 2). Iron deficiency is common in Crohn's disease independent of treatment, so confounding by indication is presumed; a primary iron-prevalence source was not opened (the identified source returned 402), so no prevalence figure is stated. A 1997 Annals trial and other IBD anemia hits did not report budesonide iron indices and were not cited.

Channels tried

WebSearch: one budesonide hemoglobin/anemia/ferritin query returned IBD iron-therapy and budesonide efficacy trials without iron indices; class-level query on glucocorticoids and hepcidin not executed (search budget exhausted). PubMed 403/429; Crossref 429; Europe PMC 429; Semantic Scholar 429; OpenAlex search 429; Unpaywall no response; direct fetch of a Crohn's B12/folate paper returned 402; one PMC article returned a bot-verification page. DailyMed and FDA label opened.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk (mixed direction, mostly non-IBD or non-human evidence)

Yellow — Low

See study details

Budesonide acts in the gut lumen and has been associated with microbiome shifts in microscopic colitis and in a ground squirrel model, but a 40-strain in vitro screen and an ulcerative colitis FMT trial found no corresponding effect.

Full detail and limits

Limits on what this shows

Null and negative findings: A 40-strain intestinal bacterial screen (Maier 2018, reported in [15], primary not opened) detected no alteration in microbial growth with budesonide. Ground squirrel authors report no overall community shift [16]. The FMT trial found no engraftment effect [17].
At-risk subgroups: Not defined by the available evidence.

Regulatory status

No microbiome statement in the Entocort EC label sections extracted [1][3].

Population evidence

Microscopic colitis cross-sectional study (budesonide-treated patients; described in two reviews [14][15], primary article not opened): treatment was associated with higher Ruminococcaceae and Ruminococcus 2, lower Faecalibacterium and higher diversity, moving toward healthy controls; sample size not captured. Tier A cohort for budesonide but a different disease and cross-sectional. Animal: 40 13-lined ground squirrels, 20 on budesonide about 1 mg/kg for 10 weeks, lower cecal alpha diversity and higher Marvinbryantia and Enterococcus, no colon or mucosal change [16]. Tier B. Ex vivo fecal cultures: budesonide fully degraded within 7 hours [15] (Tier B). Human RCT: 24 patients with active ulcerative colitis, 13 on budesonide 9 mg/day for 3 weeks before FMT; pretreatment did not increase donor engraftment [17].

Mechanism

Plausible by site: the drug is released in the intestinal lumen; direct bacterial effects were not seen in vitro and indirect effects via reduced inflammation are the more likely route [15]. The sources do not isolate which.

Class extrapolation

None applied; both reviews state that corticosteroid microbiome findings are inconsistent and call for drug-specific longitudinal IBD studies [14][15].

Counter-evidence held on record

Inflammation resolution alone alters the microbiome, so drug and disease effects cannot be separated in treated patients. The observed direction in microscopic colitis (toward controls) is the reverse of a harm signal. This is a monitoring-level observation, not a deficiency claim, and it does not imply that any probiotic or fiber product is needed.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production (class extrapolation, direction depends on exposure)

Yellow — Low

Evidence: class extrapolation

The same glucocorticoid models describe enhanced ATP production with short exposure and decreased production with long exposure; no study measured ATP in budesonide-treated people.

Full detail and limits

Limits on what this shows

Null and negative findings: None located; ATP was not measured in any budesonide clinical study found.
At-risk subgroups: Not defined.

Regulatory status

No statement in the label. Fatigue is listed at 5% in 8-week Crohn's trials and is a symptom, not an ATP measure [1].

Population evidence

Tier C: review [20] (dexamethasone, corticosterone, cortisol; no budesonide) reporting enhanced mitochondrial ATP production with short exposure and decreased ATP with long exposure. Tier B budesonide in vitro: [19] shows OXPHOS gene upregulation, not ATP measurement.

Mechanism

Respiratory chain activity and membrane potential regulated by mitochondrial glucocorticoid receptors [20]. Not demonstrated for budesonide.

Class extrapolation

Labeled class extrapolation. Cohort test: drugs studied dexamethasone, corticosterone, cortisol; budesonide absent [20]. Rests on the same source as Mitochondrial burden; recorded in the Overlap map and not counted as independent confirmation. Kept as a separate entry from Mitochondrial burden and Oxygen delivery/utilization per Hard Rule 7.

Counter-evidence held on record

Fatigue in IBD is multifactorial (anemia, inflammation, sleep), so the label's 5% fatigue figure cannot be read as an energy-production signal. Low energy is not evidence of reduced ATP production. No CoQ10, carnitine or other energy supplement is supported by this entry.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No hemoglobin, hematocrit or oxygenation study attributable to budesonide was found; the label's anemia laboratory listing is an outcome in an inflammatory disease population.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition: no Tier B or C evidence located to support a yellow, and no circulating claim about budesonide and oxygen-carrying capacity located. Tooling-limited and provisional; not a finding of safety.

What was found

Anemia appears among Entocort EC laboratory abnormalities at 1% or more with no comparator rate extracted [3]. No budesonide study reporting hemoglobin trajectories was opened. Any such change in Crohn's disease is confounded by inflammation, blood loss and iron/B12/folate deficiency of the disease. The drug's intended anti-inflammatory action is not an oxygen-delivery deficiency (Hard Rule 2). Kept separate from ATP production (Hard Rule 7).

Channels tried

WebSearch: one anemia/hemoglobin budesonide query, no usable budesonide-specific hemoglobin source; class-level erythropoiesis query not executed (search budget exhausted). PubMed 403/429; Crossref 429; Europe PMC 429; Semantic Scholar 429; OpenAlex search 429; Unpaywall no response; a Japanese phase 3 budesonide trial page returned a bot-verification page and could not be read. DailyMed and FDA label opened.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Budesonide depletes calcium and vitamin D (or reduces vitamin D effectiveness and raises calcium excretion)
Where it comes from: Drug-interaction checker text: "systemic corticosteroids may reduce the effects of vitamin D", presented as a budesonide with calcium/vitamin D interaction [24]. Tier D, an aggregator page without drug-specific primary citations.
Why it fails: The source sentence concerns systemic corticosteroids, not oral budesonide (9% to 21% bioavailable, 80% to 90% first pass). Neither label states a calcium or vitamin D effect [1][3][4]. A matched cohort of long-term oral budesonide users found no major difference in final vitamin D or PTH versus unexposed IBD patients, and PTH rising would be the companion marker of true mobilization [10]. Low vitamin D in Crohn's disease and ulcerative colitis is disease-linked [23]. This rebuttal applies to budesonide only; it does not address systemic corticosteroids, which were not reviewed here.
Swallowed corticosteroid reduces calcium absorption and lowers DHEA, listed on a budesonide consumer page
Where it comes from: Consumer health page titled Budesonide whose statements are about inhaled beclomethasone [25]. Tier D.
Why it fails: The statements name beclomethasone inhalers, not budesonide or oral GI formulations; DHEA is a hormone, not a nutrient; the page cites no budesonide-specific measurement. The claim fails for this drug and scope.

How the body handles this medication

Metabolism: Rapid, extensive biotransformation mainly by CYP3A4 to 6-beta-hydroxy budesonide and 16-alpha-hydroxy prednisolone, each with less than 1/100 of parent glucocorticoid activity. High hepatic clearance (0.9 to 1.8 L/min).[1] FDA Entocort EC label, section 12.3
Bioavailability and first pass: Mean oral bioavailability 9% to 21% (9% healthy volunteers, 21% Crohn's disease); first-pass metabolism 80% to 90%; plasma protein binding 85% to 90%.[1][2] label, section 12.3
CYP induction or inhibition: Budesonide is described as a CYP3A4 substrate. The extracted label sections do not report induction or inhibition of any CYP enzyme by budesonide. This is an absence in the extracted text, not a verified negative.[3] drugs.com Entocort EC prescribing information
Elimination: About 60% of recovered radioactivity in urine as metabolites; no unchanged budesonide detected in urine; remainder in feces. Oral half-life 6.3 hours. No renal tubular water or electrolyte handling is described in the extracted label text.[1] label, section 12.3
Site of release and absorption: Entocort EC coating dissolves at pH above 5.5 in the duodenum with gradual intestinal release; Uceris is a colonic-release tablet (peak concentration averages 13.3 hours). Both are designed for local action. No named absorption transporter is described. High-fat meal delayed Tmax by 2.3 hours without significant AUC change.[1][2][4]
Interactions and special populations: Ketoconazole raises AUC eight-fold; grapefruit juice about two-fold; cimetidine raises AUC 31%; omeprazole has no significant effect. Moderate hepatic impairment (Child-Pugh B) gives 3.5-fold AUC; pediatric patients have 17% higher exposure and greater cortisol suppression than adults. No mineral or antacid chelation interaction is reported in the extracted text.[1][2][4]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Drug's own labeled effect
Adrenal axis and hypercorticism
Adrenal suppression is an intended-pharmacology, labeled effect, not a nutrient entry. The label directs monitoring for hypercorticism and adrenal axis suppression and stress-dose consideration around surgery [1][4]. Highest risk: pediatric patients, hepatic impairment, strong CYP3A4 inhibitors and grapefruit juice [1][2].
Lab
Serum potassium
Check when diarrhea is heavy, after bowel resection, or with potassium-wasting co-medications. A low value is a disturbance to be interpreted by the prescriber; this dossier recommends no potassium supplement [3][13].
Bone
Bone density context
Prior systemic steroid exposure, Crohn's disease and microscopic colitis each independently raise low-BMD risk [11]. The microscopic colitis meta-analysis authors suggest BMD screening at diagnosis. Budesonide-specific BMD loss was small versus prednisolone [6].
Disease-driven, not attributed
Iron, B12, folate, vitamin D
These are monitored as part of routine IBD care because the disease causes them (vitamin D: 55-study meta-analysis [23]). A low result is not evidence budesonide caused it.
Timing and separation
Interactions
No supplement separation interval was identified in the label text extracted. Avoid grapefruit juice and strong CYP3A4 inhibitors per label; pH-altering drugs may affect capsule dissolution; cimetidine raised AUC 31%, omeprazole had no effect [1][2].
Populations
Pregnancy, pediatric, hepatic
Pregnancy: animal data show fetal harm; infants exposed in utero may have hypoadrenalism. Pediatric: 17% higher exposure and possible reduced growth velocity. Child-Pugh B: 3.5-fold AUC, consider 3 mg daily; avoid in severe impairment [1]. Renal impairment was not addressed in the label text extracted.

Overlap map, to prevent double counting

Mitochondrial burden
Shares evidence with: ATP production; Oxidative stress
Note: All three rest on the same class review [20] (dexamethasone, corticosterone, cortisol) and on the same budesonide in vitro study [19]; [21] adds a second class mechanistic source on mitochondrial function only. Treat as one line of class-level evidence, not three.
ATP production
Shares evidence with: Mitochondrial burden
Note: Same source [20]; separate entry per Hard Rule 7, not independent confirmation.
Oxidative stress
Shares evidence with: Mitochondrial burden; ATP production
Note: ROS finding comes from the same review [20]; additional sources [18] (budesonide in vitro, null) and [22] (unspecified corticosteroids, IBD cross-sectional) are separate.
Bone mineral density
Shares evidence with: Reviews [7] and [12]
Note: Both reviews restate the trial in [6] (-1.04% versus -3.84%); the label sentence on BMD [1][3] also summarizes the same trial. These are one trial, not four confirmations.
Potassium
Shares evidence with: Label copies [1][2][3]
Note: The FDA label PDF, DailyMed and drugs.com page are the same label text; the case report [13] and review [12] are separate but the review's "common" statement is not an independent rate.
Gut microbiome risk
Shares evidence with: Reviews [14] and [15]
Note: Both describe the same microscopic colitis study and the same in vitro screen; counted once.
Iron; Oxygen delivery/utilization
Shares evidence with: Label anemia listing [3]
Note: The same laboratory-abnormality line is the only touchpoint for both entries; neither is graded.
Fails verification (calcium and vitamin D)
Shares evidence with: Bone mineral density
Note: Both draw on the cohort in [10]; used there for BMD and here for the vitamin D/PTH null.

All references used above

Budesonide

Findings for this medication

What the research found

Bone mineral density (outcome entry, not a calcium or vitamin D deficiency)

Potassium (low serum potassium as a loss disturbance, with strong confounders)

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden (class extrapolation, budesonide not in the studied cohort)

💥Oxidative Stress

Oxidative stress (class extrapolation, mixed direction)

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk (mixed direction, mostly non-IBD or non-human evidence)

💨Oxygen and ATP Output

ATP production (class extrapolation, direction depends on exposure)

Oxygen delivery/utilization

Claims checked and not supported

Budesonide depletes calcium and vitamin D (or reduces vitamin D effectiveness and raises calcium excretion)

Swallowed corticosteroid reduces calcium absorption and lowers DHEA, listed on a budesonide consumer page

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output